Epothilones in the treatment of ovarian cancer

Future Oncology

Volumn 7, Issue 4, 2011, Pages 559-568

  Diaz Padilla, Ivan ^a   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ixabepilone; microtubule stabilizing agent; ovarian cancer; P glycoprotein; patupilone; taxane

Indexed keywords

CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; GEMCITABINE; IXABEPILONE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; TAXANE DERIVATIVE; TRASTUZUMAB; VORINOSTAT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CENTRAL NERVOUS SYSTEM TUMOR; COLON CARCINOMA; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; GLIOMA; GYNECOLOGIC CANCER; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MICROTUBULE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EPOTHILONES; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUBULIN MODULATORS;

EID: 79953704034     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.26     Document Type: Review

References (48)

1. Bollag DM, McQueney PA, Zhu J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325-2333 (1995).
2. Fojo AT, Menefee M: Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin. Oncol. 32, S3-S8 (2005). (Pubitemid 41785440)
3. Sparano JA, Vrdoljak E, Rixe O et al.: Randomized Phase III trial of ixabepilone plus ca pecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28, 3256-3263 (2010).
4. Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents 2, 123-148 (2002). (Pubitemid 34649871)
5. Goodin S, Kane MP, Rubin EH: Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 22, 2015-2025 (2004). (Pubitemid 41095195)
6. Martello LA, Verdier-Pinard P, Shen HJ et al.: Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res. 63, 1207-1213 (2003). (Pubitemid 36355832)
7. Verrills NM, Flemming CL, Liu M et al.: Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem. Biol. 10, 597-607 (2003). (Pubitemid 36940936)
8. Kamath K, Wilson L, Cabral F et al.: βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280, 12902-12907 (2005).
9. Stalder MW, Anthony CT, Woltering EA: Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J. Surg. Res. DOI: 10.1016/j.jss.2009. 12.001 (2009) (Epub ahead of print).
10. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943 (2002). (Pubitemid 35424084)
11. Woltering EA, Lewis JM, Maxwell PJ et al.: Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann. Surg. 237, 790-798; discussion 79 8-800 (2003).
12. Lee FY, Smykla R, Johnston K et al.: Preclinical effcacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 63, 201-212 (2009).
13. Michaud LB: The epothilones: how pharmacology relates to clinical utility Ann. Pharmacother. 43, 1294-1309 (2009).
14. Altmann KH, Wartmann M, O'Reilly T Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta 1470, M79-M91 (2000). (Pubitemid 30229922)
15. Ferretti S, Allegrini PR, O'Reilly T et al.: Patupilone induced vascular disruption in orthotopic rodent tumor mod els detected by magnetic resonance imaging and interstitial fuid pressure. Clin. Cancer Res. 11, 7773-7784 (2005). (Pubitemid 41611621)
16. Willett CG, Boucher Y, di Tomaso E et al.: Direct evidence that the VEGF-specifc antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004). (Pubitemid 38524883)
17. Taghian AG, Abi-Raad R, Assaad SI et al.: Paclitaxel decreases the interstitial fuid pressure and improves oxygena tion in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23, 1951-1961 (2005). (Pubitemid 46211374)
18. Rubin EH, Rothermel J, Tesfaye F et al.: Phase I dose-fnding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. 23, 9120-9129 (2005).
19. Ten Bokkel Huinink WW, Sufiarsky J, Smit WM et al.: Safety and effcacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a Phase I, open-label, dose-escalation study. J. Clin. Oncol. 27, 3097-3103 (2009).
20. Forster M, Kaye S, Oza A et al.: A Phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin. Cancer Res. 13, 4178-4184 (2007). (Pubitemid 47105981)
21. Aghajanian C, Burris HA 3rd, Jones S et al.: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol. 25, 1082-1088 (2007). (Pubitemid 46596760)
22. Schelman W, Morgan-Meadows S, Bailey H et al.: A Phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 62, 727-733 (2008).
23. Hofstetter B, Vuong V, Broggini-Tenzer A et al.: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin. Cancer Res. 1 1, 1588-1596 (2005). (Pubitemid 40315244)
24. Fogh S, Machtay M, Werner-Wasik M et al.: Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 77, 1009-1016 (2010).
25. Sridhar SS, Hotte SJ, Kollmannsberger CK et al.: Preventing patupilone-induced diarrhea with high-dose corticosteroids. J. Clin. Oncol. 28, Abstract E13069 (2010).
26. Roche H, Yelle L, Cognetti F et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog as frst-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25, 3415-3420 (2007). (Pubitemid 47310877)
27. Thomas E, Tabernero J, Fornier M et al.: Phase II c linical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25, 3399-3406 (2007). (Pubitemid 47310875)
28. De Geest K, Blessing JA, Morris RT et al.: Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J. Clin. Oncol. 28, 149-153 (2010).
29. Smit WM, Sufiarsky J, Werner TL et al.: A Phase II study evaluating the safety and effcacy of patupilone in patients with platinum re fractory/re sistant ovarian, primary fallopian, or peritoneal cancer. J. Clin. Oncol. 25, Abstract 5563 (2009).
30. Colombo N, Schwartz PE, Barnias A et al.: Results of a randomized, open-label, Phase III trial of patupilone versus pegylated liposomal doxorubicin in taxane/platinum refractory/resistant patient s with recurrent ovarian, fallopian tube, or peritoneal cancer. Ann. Oncol. 21, LBA24 (2010).
31. Ferrandina G, Ludovisi M, Lorusso D et al.: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26, 890-896 (2008). (Pubitemid 351398081)
32. Miller DS, Blessing JA, Krasner CN et al.: Phase II evaluation of pemetrexed in the treatment of recurrent or persisten t platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 27, 2686-2691 (2009).
33. Gordon AN, Tonda M, Sun S et al.: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95, 1-8 (2004). (Pubitemid 39286270)
34. Egerton N: Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother. Pharmacol. 66, 1005-1012 (2010).
35. Hussain A, DiPaola RS, Baron AD et al.: Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann. Oncol. 20, 492-497 (2009).
36. Vansteenkiste J, Lara PN Jr, Le Chevalier T et al.: Phase II clinical trial of the epothilone B anal og, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed frst-line platinum-based chemotherapy J. Clin. Oncol. 25, 3448-3455 (2007). (Pubitemid 47310882)
37. Hussain M, Tangen CM, Lara PN Jr et al.: Ix abepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0 111. J. Clin. Oncol. 23, 8724-8729 (2005). (Pubitemid 46211517)
38. Rosenberg JE, Weinberg VK, Kelly WK et al.: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110, 556-563 (2007). (Pubitemid 47106144)
39. Dizon DS, Blessing JA, McMeekin DS et al.: Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J. Clin. Oncol. 27, 3104-3108 (2009).
40. Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003). (Pubitemid 46606249)
41. Parmar MK, Ledermann JA, Colombo N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovar ian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361, 2099-2106 (2003).
42. Rose PG, Blessing JA, Ball HG et al.: A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 88, 130-135 (2003). (Pubitemid 36263370)
43. 2) in platinum and paclitaxel-resis tant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study Gynecol. Oncol. 101, 436-440 (2006). (Pubitemid 43729968)
44. Baselga J, Zambetti M, Llombart-Cussac A et al.: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 27, 526-534 (2009).
45. Szakacs G, Paterson JK, Ludwig JA et al.: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006). (Pubitemid 43336035)
46. Pusztai L: Markers predicting clinical beneft in breast cancer from microtubule-targeting agents. Ann. Oncol. 18(Suppl. 12), XII15-XII20 (2007).
47. Tommasi S, Mangia A, Lacalamita R et al.: Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int. J. Cancer 120, 2078-2085 (2007). (Pubitemid 46555844)
48. Rouzier R, Rajan R, Wagner P et al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad. Sci. USA 102, 8315-8320 (2005). (Pubitemid 40800086)